📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Northwest Biotherapeutics

1.1 - Company Overview

Northwest Biotherapeutics Logo

Northwest Biotherapeutics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of cancer immunotherapy products, focused on developing and commercializing personalized vaccine candidates: DCVax-L for newly diagnosed glioblastoma multiforme (GBM) in a Phase III trial; DCVax-Direct for direct injection into inoperable solid tumors in a Phase I/II trial; and DCVax-Prostate targeting late-stage, hormone-independent prostate cancer using a proprietary PSMA antigen.

Products and services

  • DCVax-Direct: Engineers a clinical-stage, direct-injection immunotherapy for inoperable solid tumor cancers, currently in a Phase I/II trial
  • DCVax-L: Produces a personalized vaccine for newly diagnosed GBM, undergoing evaluation in a Phase III trial
  • DCVax-Prostate: Constructs a proprietary-antigen, PSMA-based vaccine targeting late-stage, hormone-independent prostate cancer, utilizing prostate-specific membrane antigen as the vaccine target

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Northwest Biotherapeutics

Atrin Pharmaceuticals Logo

Atrin Pharmaceuticals

HQ: United States Website
  • Description: Provider of biopharmaceutical discovery and development for innovative cancer treatments. The privately held company, based in Doylestown, PA, is engaged in the discovery and development of treatments for cancer, with its most advanced program focused on a new class of highly specific compounds.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Atrin Pharmaceuticals company profile →
Flare Therapeutics Logo

Flare Therapeutics

HQ: United States Website
  • Description: Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Flare Therapeutics company profile →
ScreenPoint Medical Logo

ScreenPoint Medical

HQ: The Netherlands Website
  • Description: Provider of deep learning and image analysis technology for automated reading of mammograms and digital breast tomosynthesis. Offers Transpara software that assists radiologists by categorizing and prioritizing exams, differentiating those with a high probability of suspicious findings, and providing workflow enhancements, combining machine learning advances with very large, well-curated digital image databases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ScreenPoint Medical company profile →
Oncimmune Logo

Oncimmune

HQ: United Kingdom Website
  • Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Oncimmune company profile →
Compass Therapeutics Logo

Compass Therapeutics

HQ: United States Website
  • Description: Provider of immune system–targeting therapeutics and antibody engineering platforms. Pipeline: CTX-009, a DLL4/VEGF-A bispecific showing benefit in colorectal and gastric cancers; CTX-471, a CD137 agonist for melanoma with U.S. studies planned H2 2024; and CTX-8371, a PD-1/PD-L1 bispecific in preclinical development for solid tumors. Platforms: StitchMabs for bispecifics, common light chain discovery, and human display for antibody tuning.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Compass Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Northwest Biotherapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Northwest Biotherapeutics

2.2 - Growth funds investing in similar companies to Northwest Biotherapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Northwest Biotherapeutics

4.2 - Public trading comparable groups for Northwest Biotherapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Northwest Biotherapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Northwest Biotherapeutics

What does Northwest Biotherapeutics do?

Northwest Biotherapeutics is a provider of cancer immunotherapy products, focused on developing and commercializing personalized vaccine candidates: DCVax-L for newly diagnosed glioblastoma multiforme (GBM) in a Phase III trial; DCVax-Direct for direct injection into inoperable solid tumors in a Phase I/II trial; and DCVax-Prostate targeting late-stage, hormone-independent prostate cancer using a proprietary PSMA antigen.

Who are Northwest Biotherapeutics's competitors?

Northwest Biotherapeutics's competitors and similar companies include Atrin Pharmaceuticals, Flare Therapeutics, ScreenPoint Medical, Oncimmune, and Compass Therapeutics.

Where is Northwest Biotherapeutics headquartered?

Northwest Biotherapeutics is headquartered in United States.

How many employees does Northwest Biotherapeutics have?

Northwest Biotherapeutics has 1,000 employees 🔒.

When was Northwest Biotherapeutics founded?

Northwest Biotherapeutics was founded in 2010 🔒.

What sector and industry vertical is Northwest Biotherapeutics in?

Northwest Biotherapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Northwest Biotherapeutics

Who are the top strategic acquirers in Northwest Biotherapeutics's sector and industry

Top strategic M&A buyers and acquirers in Northwest Biotherapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Northwest Biotherapeutics?

Top strategic M&A buyers groups and sectors for Northwest Biotherapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Northwest Biotherapeutics's sector and industry vertical

Which are the top PE firms investing in Northwest Biotherapeutics's sector and industry vertical?

Top PE firms investing in Northwest Biotherapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Northwest Biotherapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Northwest Biotherapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Northwest Biotherapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Northwest Biotherapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Northwest Biotherapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Northwest Biotherapeutics?

The key public trading comparables and valuation benchmarks for Northwest Biotherapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Northwest Biotherapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Northwest Biotherapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Northwest Biotherapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Northwest Biotherapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Northwest Biotherapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Northwest Biotherapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Northwest Biotherapeutics